Around 1.5 million Brits are now taking weight-loss drugs, such as Mounjaro, and pharmacists are warning users to be careful in the heatwave ...

Martin Vollmer, biopharma program manager at Agilent Technologies, spoke to LCGC International about the evolving importance of glucagon-like peptide-1 (GLP-1) therapeutics and the challenges they ...

While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle East, now can still be a good time to invest in growth s ...

COPENHAGEN, Denmark I June 18, 2025 I Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development ...

At HLTH Europe 2025, experts warned that stigma, cost barriers, and lack of support are hindering the wider use of GLP-1s in ...

Telehealth geriatric assessment significantly improves short-term outcomes for older adults with advanced cancers … JAMA releases feeding guide for advanced dementia patients and families … Heart ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

Wellness influencer Janelle Rohner has seen the internet's criticism after revealing she micro-dosed GLP-1 to lose weight.

Wellness influencer Janelle Rohner has seen the internet’s criticism after revealing she micro-dosed GLP-1 to lose weight.

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.